This resolution acknowledges Charcot-Marie-Tooth disease (CMT) as a significant neurological disorder that impacts an estimated 126,000 individuals in the United States and millions worldwide. It highlights that CMT, an inherited condition damaging peripheral nerves, saw a decrease in federal research funding from 2021 to 2022 despite its widespread impact and the fact that its specific gene has not yet been identified. The House of Representatives expresses the critical need for robust funding for CMT research, specifically at the National Institute of Neurological Disorders and Stroke (NINDS) within the National Institutes of Health (NIH). The resolution further advocates for continued investment in research efforts to tackle CMT and other rare diseases for which there is currently no cure, underscoring the importance of dedicated resources to advance understanding and treatment options.